Y-mAbs Therapeutics (NASDAQ: YMAB) reported Q1 EPS of ($0.15), $0.01 worse than the analyst estimate of ($0.14). Revenue for the quarter came in at $19.93 million versus the consensus estimate of $22.84 million.

GUIDANCE:

Y-mAbs Therapeutics sees FY2024 revenue of $95-100 million, versus the consensus of $96.87 million.

For earnings history and earnings-related data on Y-mAbs Therapeutics (YMAB) click here.